- Conditions
- Diabetes Type 2
- Interventions
- Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 677 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 104
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes
- Interventions
- Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- InsuPatch
- Device
- Lead sponsor
- Insuline Medical Ltd.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 1 Diabetes
- Interventions
- Pramlintide, Glargine, Lispro, Aspart
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 12 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Technosphere Insulin, Basal insulin
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
- Conditions
- Diabetes, Type I
- Interventions
- Technosphere Insulin, Active comparator
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 589 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 61
- States / cities
- Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more
- Conditions
- Healthy Subjects
- Interventions
- Insulex® R (soluble human insulin, biosimilar), Humulin® R (soluble human insulin, biosimilar)
- Drug
- Lead sponsor
- Laboratorios Pisa S.A. de C.V.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Type 1 Diabetes
- Interventions
- Pramlintide, Exenatide, Insulin
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Diabetes Mellitus
- Interventions
- Degludec, Standard long-acting
- Drug
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin, Pramlintide + Insulin
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Pump (Medtronic Minimed Paradigm® VEO)
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Albany, New York • Syracuse, New York
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- BIOD-123, Lispro (Humalog)
- Drug
- Lead sponsor
- Biodel
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 34
- States / cities
- Anaheim, California • Chula Vista, California • Concord, California + 28 more
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Glulisine (Apidra)
- Drug
- Lead sponsor
- Carl T. Hayden VA Medical Center
- Federal
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Regular pasta, High protein pasta, White rice
- Other
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- DKA
- Interventions
- Insulin Glargine
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Saint Louis Park, Minnesota
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Humalog, Novolog, BC222 insulin lispro, Bionic Pancreas
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
- Interventions
- Subcutaneous Insulin, Inhaled Insulin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 77 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 77
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more
- Conditions
- Type2 Diabetes
- Interventions
- Afrezza Inhalant Product
- Drug
- Lead sponsor
- Model Clinical Research LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 37
- States / cities
- Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Interventions
- TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Type1diabetes
- Interventions
- Quick Bolus, Standard Bolus
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Ultra-Rapid Lispro, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 32
- States / cities
- Concord, California • Fresno, California • Greenbrae, California + 28 more
- Conditions
- Type 2 Diabetes
- Interventions
- Semaglutide, Insulin Degludec, Insulin aspart
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio